The changes that occur in body fluid and tissue enzymes in malignant disease may assist diagnosis and therapy and may provide insight into the metabolism of neoplastic tissue.
Diagnostic applications

Serum Enzymes
The serum of patients with malignant disease may show elevation of both glycolytic and oxidative enzymes even when secondary deposits (metastases) are absent (Rose et al, 1961; Schwartz et ai, 1962 a and b) . Phosphohexose isomerase (PHI) and aldolase are the most frequently elevated (approximately 50 %). The incidence of raised values varies with the site of primary growth. This may be related to differing enzyme activities of different tumour cell types, the mass reached by different tumours before metastasising and the ease of clinical detection prior to metastasis or massive enlargement. The greater the mass of enzyme containing tissue, the more frequent is enzyme elevation. Data relating the incidence of serum enzyme elevation to the ease of clinical diagnosis is regrettably lacking.
When metastasis takes place either to bone or liver the incidence of elevation of glycolytic and oxidative enzymes markedly increases. For the most sensitive enzyme (PHI) an incidence of 80 %has been recorded with secondary deposits at either site. Glutamic-oxaloacetic transaminase shows significant elevation (about 50 %), only in the presence of hepatic metastases. This indicates that the enzyme is liberated from invaded liver tissue rather than produced by the tumour.
For the detection of liver secondaries the enzyme leucine -aminopeptidase (LAP) has proved most valuable (Rutenburg et ai, 1964, a and b) . 82 % of non-jaundiced patients with liver secondaries may show elevated values compared with 6 % of non-jaundiced cancer subjects with no evidence of hepatic metastases. In jaundiced patients, LAP is even more frequently elevated. Following the removal of a primary tumour, 18 % of patients may show LAP elevation 2-9 months before the development of clinically obvious hepatic secondaries, thus indicating that LAP determination is of value in pre-clinical diagnosis.
In the detection of secondaries in bone alkaline phosphatase determination may be helpful (Gutman, 1959) . For example some 90% of cases of untreated cancer of the prostate with secondaries to bone show raised levels (Woodard, 1959) . The differentiation of alkaline phosphatase elevation due to bone secondaries from that due to liver deposits (in which the enzyme may also be elevated) may be achieved by combining its determination with that of LAP or the specific phosphatase 5'-nucleotidase. These latter enzymes are not significantly elevated in bone lesions. Isoenzyme fractionation of alkaline phosphatase may also permit identification of its tissue of origin.
Serum enzymes have also been used to follow the clinical course of cancer and patient response to treatment. Acid and alkaline phosphatase dete~ination in cancer of the prostate are familiar examples.
PHI determination has however, proved a superior enzyme for following the clinical course of cancer of the prostate (Schwartz et ai, 1963) and its response to treatment, and is also the enzyme determination of choice for following cancer of the breast (Griffith and Beck, 1963) .
Serum enzyme determinations may be" of prognostic value. For example, in cancer of the lung serum lactate dehydrogenase (LD) is seldom raised in the absence of metastases. An elevated serum LD, therefore, carries a bad prognosis, and the majority of such patients do not survive six months (Hinton, 1965) . PHI isoenzyme fractionation may also indicate those cancer patients who may respond to chemotherapy (Winsten et ai, 1965) . Patients who respond show serum PHI isoenzymes similar to normal, whereas those who do not have an absence of normal fractions.
White Cell Enzymes
The staining of neutrophils for alkaline phosphatase is useful in hsematology for the investigation of leukemias (Keane, 1965) . In acute and chronic myeloid leukemia, decreased neutrophil enzyme activity contrasts with the increased activity oflymphoblastic leukemia and the normal or increased values of chronic lymphatic leukeernia.
Increased total LD activity and abnormal LD !soenzyme patterns are found in the neutrophils 10 acute and chronic myeloid leukemia (Dio-guardi et aI, 1962) and are accompanied by corresponding changes in serum LD (Wr6blewski, 1957; Hill, 1961) . Abnormal LD isoenzyme patterns are found in the lymphocytes in chronic lymphatic leukemia but total lymphocytic LD activity is not increased (Dioguardi and Agostoni, 1965) . Red Cells Red cell enzyme studies have not proved diagnostically valuable in malignant disease. As association between a high incidence if cancer and genetic red cell LD polymorphism has been reported (Latner, 1964) . Other Body Fluids In the examination of other body fluids for the detection of malignancy at specific sites, LD has been studied in effusions, urine, gastric juice and cerebro-spinal fluid and 6-phosphogluconate dehydrogenase (6-PGDH) measured in vaginal fluid. Pleural and Peritoneal Effusions In pleural and peritoneal effusions, the finding of effusion LD activity greater than that of simultaneously sampled serum was originally claimed to indicate that the effusion was malignant, no increase being found in non-inflammatory, non-malignant effusions (Wr6blewski, 1957; Wr6blewski and Wr6blewski, 1958) . Further studies (Horrocks et al, 1962; Brauer et al, 1963) have, however, indicated a significant percentage of raised values (average 10%) in benign non-inflammatory effusions, frequent elevation (about 40 %) in inflammatory effusions and normal values in malignant effusions (40%) even those containing malignant cells (25 %). Examination of effusion LD isoenzymes has failed to improve diagnostic accuracy (Forshall, 1965) for although slow-moving isoenzymes characteristic of malignancy may be increased in malignant effusions (Richterich et al, 1961) they may also be present in inflammatory effusions, possibly coming from neutrophils. Urine The original claims (Wacker and Dorfman, 1962 ) that LD activity is almost invariably raised in the urine of patients with cancer of the kidney or urinary bladder, and is rare in benign urinary tract disease simulating cancer, have also not been substantiated (Riggins and Kiser, 1963, Rosalki, unpublished observations. Mirabile et ai, 1966) .LD isoenzyme studies of urine have not provided additional diagnostic differentiation (Riggins and Kiser, 1963) . Spuriously low LD activity may result from examination of acid urine (unpublished observations).
Gastric Juice
The increased LD activity that has been noted in gastric juice in patients with cancer of the stomach (Schenker, 1959) has not proved of diagnostic value, since normal values may be found in undifferentiated gastric cancers (Piper et al, 1963) and raised values occasionally in pernicious anemia and gastric ulcer. Cerebro-spinal Fluid Whilst LD activity in C.S.F. may be increased in the majority of patients with metastases in brain tissue (Wr6blewski et ai, 1958) the increased values also encountered in cerebral inflammatory or vascular disease and the normal values frequent in primary brain tumours renders its determination of little diagnostic help. Vaginal Fluid 6-PGDH elevation is found in a very high proportion (over 95 %) of invasive cancer of the uterine cervix (Bonham and Gibbs, 1962; Cameron and Husain, 1965) , however, only 50% of patients with pre-invasive cancer show enzyme elevation (Cameron and Husain, 1965, Hoffman and Merritt, 1965) . Increasing experience has shown a much higher incidence of false positives (about 30 % overall) than originally claimed, elevated values being frequent in vaginal bleeding and inflammation, during hormone therapy and after the menopause (Bell and Egerton, 1965) . There seems little doubt that cervical cytology is a superior screening procedure for cancer of the cervix. Therapeutic Applications Increased enzyme activity in cancer tissue may render the malignant process especially susceptible to therapy as abnormally active enzyme regulated metabolic pathways are particularly vulnerable to chemo-therapeutic attack. Increased enzyme activity may also be associated with drug resistance. For example, the development of increased folate reductase activity in leukemic cells produces resistance to amethopterin. Low enzyme activity associated with susceptibility has been found with 8-azaguanine which is effective against tumours low in guanase (Herschberg, 1952) .
An effect which has proved therapeutically useful has been the finding that inactive nontoxic drugs may be selectively converted into their active, but toxic form, at the site of, and as the result of tumour enzyme activity (Witten et al, 1962) . In this way systemic toxic effects are avoided.
In vitro, enzyme systems have been used for anti-cancer drug screening. Brain tissue with an LD isoenzyme pattern similar to that found in malignant tissues has been used in this way . Compounds inhibiting the slow-moving brain isoenzymes have been investigated for their anti-cancer properties. Serum PHI fractionation in cancer patients may also select those patients who respond to chemotherapy (Winsten et ai, 1965) .
Biological Significance
The abnormal enzyme activity that may occur in tumour tissue gives a clue to the abnormally active metabolic pathways therein. The finding of normal LD enzyme activity in mucosal surfaces which have formed tumours suggests that the malignant process does not originate as the result of pre-existing enzyme abnormality (Hoch-Ligeti et ai, 1965) .
Increased LD activity and abnormal LD isoenzymes have been reported in tumour free areas adjacent to cancer tissue . This may be the result of diffusion, spread which as escaped histological detection, or true transformation. Similar changes in tumour free organs remote from the primary growth have been found and interpreted as due to a fundamental metabolic change (Hoch-Ligeti et al, 1965) . However, an origin from destroyed microscopic tumour emboli appears possible.
The abnormal LD isoenzyme patterns which are a feature of malignant tumours (Pfleiderer and Wachsmuth, 1961; Richterich and Brauer, 1963 ) may be adaptive in origin since these slowmoving LD fractions are those which function best under the anarobic conditions generally prevailing in malignant tissues. These fractions sometimes show abnormal physical properties indicating disturbed protein synthesis (Starkweather and Schoch, 1962) . A similarity of tumour LD isoenzymes to that of abnormal red cell isoenzymes in a family with genetic red cell LD polymorphism and a high incidence of cancer may also suggest an occasional genetically determined association between cancer and abnormal LD isoenzyme patterns (Latner, 1964) . 
